In recent years, the therapy for patients with metabolic syndrome, which is a risk factor for cardiovascular complications, has become a challenge. Doxazosin – a selective α-adrenergic receptor antagonist, has emerged as a promising research target in the context of metabolic syndrome. It is pleiotropic action contributes to the reduction of metabolic syndrome indices. The results of clinical trials allow the construction of a promising, highly effective, and above all safe therapy in this group of patients.
Metabolic Syndrome as a Risk Factor for Developing Benign Prostatic Hyperplasia-A Simple, Non-invasive Method of Transabdominal Ultrasonography for BPH-
